Prevent preclinical drug development program: cgmp production of vaccines and biologicals for cancer prevention
Ended Awarded Last action
- Contract number
- 75N91019D00025
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 1 $3,873,113 obligated
Award facts
- Opportunity
-
- N01CN8700618 Solicitation number
- Combined order value
-
- $3,873,113 Current, with exercised options
- $4,174,178 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 5% used
- $74,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The contract, valued at up to $74,995,000, is a multiple award with Advanced Bioscience Laboratories, Inc. (ABL) as the prime contractor.
The contract supports the PREVENT Cancer Preclinical Drug Development Program, with the objective of cGMP production of vaccines and biologicals for cancer prevention. Key products and services include the manufacture of a vaccine targeting frame-shift mutations characteristic of tumors with microsatellite instability, as well as a range of other preclinical and clinical development support services such as process development, analytical testing, stability studies, and project management for infectious disease countermeasures and cancer-related therapeutics. The contract has a current period of performance from September 2019 to July 2020, with potential extension through May 2024. There is no set-aside designation indicated for this contract or the specific task order awarded to date, valued at $4,174,177.97.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Award of task order #2 (manufacture of a vaccine targeting frame-shift mutations characteristic of tumors with… | National Cancer Institute (NIH) | $3,873,113 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91019D00025?
75N91019D00025 was awarded to Advanced Bioscience Laboratories, Inc. by National Cancer Institute (National Institutes of Health) on August 14, 2019.
How much is contract 75N91019D00025 worth?
Orders under 75N91019D00025 have obligated $3,873,113. Their combined potential value, with all options, is $4,174,178. 75N91019D00025's own ceiling is $74,995,000.
How many orders have been placed under contract 75N91019D00025?
1 order has been placed under 75N91019D00025, the latest on September 19, 2019.
Who can order from contract 75N91019D00025?
75N91019D00025 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91019D00025 part of a contract vehicle?
Yes. 75N91019D00025 is part of PREVENT Cancer Preclinical Drug Development Program.
Was contract 75N91019D00025 competed?
The extent of competition for 75N91019D00025 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV